Home / Resource Library / Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Results of a study investigating CAR T lisocabtagene maraleucel for treatment of relapsed large cell B-cell lymphomas.